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Brief Technique ReportsAlthoughourgraft insertion technique requiresgraft-to-graft
anastomosis between the graft anastomosed to the LVOT
and the composite graft, this graft-to-graft anastomosis can
be easily performed with continuous over-and-over sutures.
The aortic valve allograft is considered one of the best
choices for avoiding recurrence of infection in cases of
PVE with extensive tissue destruction. However, in addition
to the allograft being hard to come by, an irregular suture
line of the aortic annulus after aggressive debridement
would make the allograft prone to distortion. In such
complicated cases our technique should be a good alterna-
tive. When resection of the severe root abscess results in
a defect of the intervalvular fibrous body, reconstruction
through the aortic root and dome of the atrium is mandatory.
We believe our technique can be applied together with
atrioventricular reconstruction.
Another advantage of our graft insertion technique is that
a valve larger than the LVOT can be inserted in patients with
small aortic roots. In such a case the graft anastomosed to
the LVOT can be cut on the bias to receive a larger stentless
valve or composite graft containing a valve larger than the
LVOT, whereas without the connecting graft, the composite
graft with the valve would have to be the same diameter as
the LVOT.From the Department of Cardiac and Thoracic Surgery of the La Timone Children’s
Hospital, Marseille, France.
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950 The Journal of Thoracic and Cardiovascular SurgComplete heart block is a common complication after re-
operation on the aortic root with a 10% to 30% occurrence
rate.1,2,4,5 We put our mattress sutures at the lower edge of
the trace of the previous valve or at a slightly higher position
in the membranous septum compared with other sutures,
and this might have led to the complete absence of heart
block in this series.
In conclusion, we present a technique that is easy and re-
liable for reinforcing the proximal anastomosis for difficult
reoperations of a damaged aortic root.References
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1416-20.How to choose the best available homograft to reconstruct the right
ventricular outflow tractDavid Kalfa, MD, Lo€ıc Mace, MD, Dominique Metras, MD, and Bernard Kreitmann, MD, Marseille,
FranceCryopreserved homografts are among the most widely
used tools to reconstruct the right ventricular outflow tract
(RVOT). Numerous risk factors for homograft degeneration
related to the operation, patient, and cardiac disease are
clearly established but remain unmodifiable. On the other
hand, risk factors related to the homograft by itself (eg, do-
nor, processing, storage) are not consensual and influence
the fate of the reconstructed RVOT through the choice ofthe homograft made by the surgeon at the time of implanta-
tion. The objective of this study was to determine the risk
factors for homograft dysfunction and failure related to
the origin, characteristics, and processing of the homograft
to help the surgeon to choose the best available homograft
for a given patient.
PATIENTS AND METHODS
A retrospective study (1993–2009) included 222 consecutive pediatric
and adult patients with implantation of a homograft for reconstruction of
the RVOT. All homografts came from a local tissue bank and were cryopre-
served in nitrogen vapor (2C/min to5C/min, up to150C/min) after
processing. Studied end points were homograft dysfunction and homograft
failure. Homograft dysfunction was defined on echocardiographic criteria:
a peak gradient of 50 mmHg or more or a regurgitation grade at least mod-
erate. Serial transthoracic echographic measurements were performed at
discharge and then yearly thereafter by the same in-house cardiologist
whenever possible using 2.5-MHz ultrasound transducers (Hewlett–
Packard Sonos 2500 System; Hewlett–Packard Co, Andover, Mass) or by
the referring cardiologist in the remaining cases. Maximum velocities
across the pulmonary valve were calculated by a continuous-wave Dopplerery c October 2011
TABLE 1. Characteristics of the patients and implanted homografts
Sex
Male: 131 (59%)
Female: 91 (41%)
Patient age at implantation
Median: 12.5 years (range: 4 days–67 years)
Mean: 15.8  15.3 years
Under 1 year: 43 (19%)
Under 10 years: 100 (45%)
Under 25 years: 164 (74%)
Main heart defects
Aortic valve disease: 107 (48%)
Pulmonary atresia and VSD: 40 (18%)
Truncus arteriosus: 28 (13%)
Tetralogy of Fallot: 23 (10%)
ccTGA: 8 (4%)
DORV: 6 (3%)
Pulmonary stenois/atresia without VSD: 4 (2%)
TGAVSD pulmonary stenosis: 3 (1.5%)
Heart defects with pulmonary hypertension: 45 (22%)
Type of surgery
Ross: 107 (48%)
Repair of pulmonary atresia and VSD: 38 (17%)
Repair of truncus arteriosus: 21 (9%)
Replacement of RV-PA tube: 14 (6%)
Pulmonary valve replacement after repair of tetralogy of Fallot: 13 (6%)
Rastelli procedure: 8 (4%)
SenningþRastelli: 5 (2%)
Homograft origin
Pulmonary: n ¼ 176 (79%)
Aortic: n ¼ 46 (21%)
Homograft diameter (mm: No. of grafts [%])
Median: 22 mm (range: 9–30 mm)
<10: 1 (0.5%)
10–14: 22 (10%)
15–19: 44 (20%)
20–24: 83 (37%)
25–29: 67 (30%)
>30: 3 (1%)
Homograft mismatch: 12 (5%)
ABO compatibility of homograft
Compatible: 140 (63%)
Noncompatible: 82 (37%)
Rhesus compatibility of homograft
Compatible: 196 (88%)
Noncompatible: 26 (12%)
Age of the homograft donor (y)
Median: 30 (range: 0.5–66)
Mean: 30  19.4
Weight of the homograft donor (kg)
Median: 53 (range: 8–95)
Sex of the homograft donor
Male: 135 (61%)
Female: 87 (39%)
Type of donor
Explanted heart from transplantation: 77 (35%)
Brain death: 133 (60%)
(Continued)
TABLE 1. Continued
Cadaver: 2 (1%)
NA: 10 (5%)
Main causes of death of the donor
Cerebrovascular accident: 38
Cranial trauma: 17
Polytraumatism: 12
Cerebral anoxia: 10
Meningitis: 4
Medium of conservation
RPMI (Roswell ParkMemorial Institute): 197 (89%) (before June 2007)
SCOT (MacoPharma, MACO-BIOTECH transplant): 25 (11%) (after
June 2007)
Decontamination time (h)
Median: 12 (range: 4–18)
Mean: 10.7  5.4
Cold ischemia time (h)
Mean: 55  26
Storage time (mo)
Median: 14 (range: 0.5–136)
Macroscopic anomalies of the homograft
Atheroma: 5
VSD (closed before implantation): 2
Fenestrated cusp: 2
Follow-up (y)
Mean: 5.5  4.5
Median: 4.7 (range: 0–17.9)
VSD, Ventricular septal defect; ccTGA, congenitally corrected transposition of great
arteries;DORV, double-outlet right ventricle; RV-PA, right ventricular–pulmonary ar-
terial; homograft mismatch is defined as a diameter of the implanted homograft<2
standard deviations or>2 standard deviations of the theoretical pulmonary annulus
diameter.
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The Journal of Thoracic and Caimaging transducer. The Bernoulli equationwas used to determine the pres-
sure gradient. Semiquantitative assessment from grade 0 (absent) to 3 (se-
vere) of homograft regurgitation was based on the length and width of the
regurgitant jet and the distance that it reaches into the RVOT on the para-
sternal short-axis view. Homograft failure was defined as the requirement
for homograft explantation, percutaneous balloon dilation, or percutaneous
valve implantation. A reintervention or percutaneous procedure was re-
quired when right ventricular/left ventricular pressure gradient was greater
than 2/3 or when the homograft displayed a moderate-to-severe regurgita-
tion. Univariate and multivariate Cox regression analysis were performed
with SPSS 15.0 software (SPSS, Inc, Chicago, Ill). Adjustment factors
for multivariate analysis were the age and sex of the patient, heart defect,
pulmonary hypertension (defined as an echographic systolic pulmonary ar-
tery pressure>30 mm Hg), type of surgery (Ross or non-Ross), period of
surgery, surgeon, sternal compression of the homograft (peroperative diag-
nosis), and changes in the homograft conservation protocol. The study was
approved by the institutional review board of the French Society of Cardio-
Vascular Surgery.RESULTS
The characteristics of the patients and implanted homo-
grafts are presented in Table 1. Overall homograft dysfunc-
tion and failure rates were 40% and 14%, respectively,
with a mean follow-up of 5.5 4.5 years. Dysfunction rates
were 65% in patientsless than 1 year old at implantation
(n ¼ 28/43), 58% in patients between 1 and 10 years old
(n ¼ 33/57), and 24% in patients more than 10 years oldrdiovascular Surgery c Volume 142, Number 4 951
TABLE 2. Significant univariate and multivariate risk factors for
homograft dysfunction and failure related to the origin,
characteristics, and processing of the homograft
Multivariate risk factors
Homograft dysfunction P value
Homograft diameter<22 mm HR: 4.5, P<103
Young age of the donor<30 y HR: 2.3, P ¼ .04
ABO incompatibility of the homograft HR: 3.1, P ¼ .003
Female sex of the donor HR: 2.3, P ¼ .02
Homograft failure
Aortic origin of the homograft HR: 4.1, P ¼ .03
Homograft diameter<22 mm HR: 6.3, P ¼ .03
Homograft mismatch HR: 8, P ¼ .02
Univariate risk factors
Homograft dysfunction
Homograft diameter<22 mm P<103
Young age of the donor<30 y P<103
ABO incompatibility of the homograft P ¼ .04
Interval between harvest and
decontamination<24 h
P<103
Decontamination time<12 h P<103
Cold ischemic time<2 d P<103
Storage time<14 mo P ¼ .01
Female sex of the donor P ¼ .04
Homograft failure
Aortic origin of the homograft P ¼ .04
Homograft diameter<22 mm P<103
Homograft mismatch P ¼ .002
Young age of the donor<30 y P<103
Interval between harvest and
decontamination<24 h
P<103
Decontamination time<12 h P ¼ .002
Cold ischemic time<2 d P ¼ .003
Homograft mismatch is defined as a diameter of the implanted homograft<2 stan-
dard deviations or>2 standard deviations of the theoretical pulmonary annulus diam-
eter. Adjustment factors for multivariate Cox regression analysis were the age and sex
of the patient, heart defect, pulmonary hypertension, type of surgery (Ross or non-
Ross), period of surgery, surgeon, anatomic distortion of the homograft, sternal com-
pression of the homograft, and changes in the homograft conservation protocol. HR,
Hazard ratio.
Brief Technique Reports(n ¼ 29/122) (P<103). Failure rates were 28% (n ¼ 12/
43), 21% (n ¼ 12/57), and 6% (n ¼ 7/122) in these 3 pop-
ulations, respectively (P<103). Dysfunction rate and fail-
ure rate in the Ross population were 27% (n¼ 32/107) and
6% (n ¼ 7/107), respectively; versus 50% (n ¼ 57/115)
and 21% (n ¼ 24/115) in the non-Ross implantation
(P<103). The aortic origin of the homograft, a too small
homograft (<22 mm or z-score<2), a too large homograft
(z-score>2), young age (<30 years), and female sex of the
donor and an ABO incompatible homograft significantly
alter the outcomes of the homograft in the multivariate
analysis (Table 2). Short decontamination, ischemia, and
storage times are significantly associated with increased
homograft dysfunction and failure in the univariate analysis
(Table 2).952 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
The use of a pulmonary homograft with a diameter com-
prised between2 andþ2 z-score of theoretical pulmonary
annulus diameter seems to be the basal requirement for an
adapted reconstruction of the RVOT by a cryopreserved
homograft. Aortic homografts and smaller homografts have
frequently been found to be associated with valve failure in
the literature, in relation with a higher risk of calcifications
for aortic homografts and the absence of growth potential.1
Our multivariate analysis also showed that oversizing
a homograft with a z-score of more thanþ2 actually de-
creased the homograft survival, as previously described in
the literature. This risk factor for homograft failure seems
to us more related to altered flow patterns than to a mechan-
ical compression of the homograft. Indeed, the cases of ster-
nal compression of the homograft that we noticed during the
operation at the time of chest closure did not occur in the
patients with implantation of a larger homograft (z-score
> 2). The discrepancy between a too large homograft and
the relative ‘‘too small’’ right ventricle and pulmonary ar-
teries could lead to a turbulent blood flow through the over-
sized homograft, causing the increase of pulmonary flow
velocity that Moidl and associates2 described in their popu-
lation of right-sided oversized homografts. Such an altered
turbulent flow within the oversized homograft might at least
partially explain the increased risk for homograft failure af-
ter implantation of such an oversized homograft.
We also advocate choosing homografts coming from
a male donor older than 30 years, if available. Initially, the
vastmajorityof studies identified an increasinghomograft do-
nor age (>50, 55, or 65 years depending on the series) as a risk
factor. However, more recent studies reported a significant
association with young donor age (<30 years or<5 years3),
as we also demonstrated in our multivariate analysis. Cryo-
preserved homografts from younger donors might be more
antigenic owing to persistence of histocompatibility antigen
expression or cell viability and thusmore subject to immuno-
logic damage.4Nevertheless, there are currently nobiological
or immunologic data allowing us to state that a younger do-
nor–derived homograft when treated identically to an adult
donor–derived one displays more antigens on its surface.
Homograft ABO incompatibility as a possible major risk
factor resulting in an important immunologic response has
been debated extensively.5 Our multivariate analysis sup-
ports this hypothesis and could lead the surgeon to prefer
choosing available ABO-compatible conduits.
The role of decontamination, ischemia, and storage times
in altered outcomes of homograft, on the basis of an exces-
sive inflammatory reaction, is still largely controversial.4
According to our study, longer processing times (decontam-
ination time>12 hours, cold ischemic time>2 days) could
be preferred in the choice of the homograft but seem to have
a smaller impact on the homograft outcome.ery c October 2011
Brief Technique ReportsOther suspected homograft-related factors such as Rhe-
sus group compatibility, type of donor (cardiac transplant
recipients, heart-beating donor), cause of donor death, and
type of conservation medium were in fact not relevant in
the statistical analysis and thus should probably not be
considered.
To conclude, the cardiac surgeon who has to reconstruct
an RVOTwith a homograft in a Ross or a non-Ross patient
could optimize his choice by opting, if available, for ABO-
compatible pulmonary homografts with a2< z-score di-
ameter<2, coming from a male donor older than 30 years,
with longer processing times.
A prospective randomized trial should be performed to
confirm these conclusions.The Journal of Thoracic and CaReferences
1. Selamet Tierney ES, Gersony WM, Altmann K, Solowiejczyk DE,
Bevilacqua LM, Khan C, et al. Pulmonary position cryopreserved homografts: du-
rability in pediatric Ross and non-Ross patients. J Thorac Cardiovasc Surg. 2005;
130:282-6.
2. Moidl R, Simon P, Kupilik N, Chevtchik O, Heinrich N, Moritz A, et al. Increased
pulmonary flow velocities in oversized homografts in patients after the Ross pro-
cedure. Eur J Cardiothorac Surg. 1997;12:569-72.
3. Niwaya K, Knott-Craig CJ, Lane MM, Chandrasekaren K, Overholt ED,
Elkins RC. Cryopreserved homograft valves in the pulmonary position: risk anal-
ysis for intermediate-term failure. J Thorac Cardiovasc Surg. 1999;117:141-6.
4. Baskett RJ, Nanton MA, Warren AE, Ross DB. Human leukocyte antigen-DR and
ABO mismatch are associated with accelerated homograft valve failure in chil-
dren: implications for therapeutic interventions. J Thorac Cardiovasc Surg.
2003;126:232-9.
5. Christenson JT, Vala D, Sierra J, Beghetti M, Kalangos A. Blood group incompat-
ibility and accelerated homograft fibrocalcifications. J Thorac Cardiovasc Surg.
2004;127:242-50.rdiovascular Surgery c Volume 142, Number 4 953
